Diabetic Neuropathy, Retinopathy, and Nephropathy

Chronic hyperglycemia contributes to diabetic neuropathy, retinopathy, and nephropathy, impacting multiple organ systems and significantly reducing quality of life. Neuropathy manifests as sensory loss, pain, or autonomic dysfunction, requiring early intervention with neuroprotective agents. Retinopathy progresses from mild non-proliferative changes to vision-threatening proliferative stages, necessitating routine ophthalmic evaluations. Nephropathy, a leading cause of end-stage renal disease, is managed through glycemic control, blood pressure regulation, and renoprotective medications like SGLT2 inhibitors. Emerging therapies, including regenerative medicine and targeted molecular interventions, offer hope for slowing or reversing disease progression. Early diagnosis and multidisciplinary management remain key in preventing irreversible damage.

Committee Members
Speaker at Diabetes 2026 - Mahir Khalil Ibrahim Jallo

Mahir Khalil Ibrahim Jallo

Gulf Medical University, Canada
Speaker at Diabetes 2026 - F Buck Willis

F Buck Willis

Christian College of Medicine, Belize
Speaker at Diabetes 2026 - Anil Harrison

Anil Harrison

Midwestern University, United States
Speaker at Diabetes 2026 - Wan Rosli Wan Ishak

Wan Rosli Wan Ishak

Universiti Sains Malaysia, Malaysia
Diabetes 2026 Speakers
Speaker at Diabetes 2026 - Mahir Khalil Ibrahim Jallo

Mahir Khalil Ibrahim Jallo

Gulf Medical University, Canada
Speaker at Diabetes 2026 - F Buck Willis

F Buck Willis

Christian College of Medicine, Belize
Speaker at Diabetes 2026 - Anil Harrison

Anil Harrison

Midwestern University, United States
Speaker at Diabetes 2026 - David Navazio

David Navazio

Gentell, United States
Speaker at Diabetes 2026 - Sujith Rajan

Sujith Rajan

NYU Long Island School of Medicine, United States
Speaker at Diabetes 2026 - David Petch

David Petch

utR Biotech, Canada
Tags

Submit your abstract Today

YouTube
WhatsAppWhatsApp